Bio-Techne Corporation

NasdaqGS:TECH Stock Report

Market Cap: US$10.9b

Bio-Techne Future Growth

Future criteria checks 1/6

Bio-Techne is forecast to grow earnings and revenue by 9.9% and 7.7% per annum respectively. EPS is expected to grow by 9.4% per annum. Return on equity is forecast to be 14.5% in 3 years.

Key information

9.9%

Earnings growth rate

9.4%

EPS growth rate

Life Sciences earnings growth16.3%
Revenue growth rate7.7%
Future return on equity14.5%
Analyst coverage

Good

Last updated11 Feb 2024

Recent future growth updates

Recent updates

We Think Bio-Techne (NASDAQ:TECH) Can Stay On Top Of Its Debt

Jan 17
We Think Bio-Techne (NASDAQ:TECH) Can Stay On Top Of Its Debt

Bio-Techne Corporation (NASDAQ:TECH) Investors Are Less Pessimistic Than Expected

Dec 30
Bio-Techne Corporation (NASDAQ:TECH) Investors Are Less Pessimistic Than Expected

Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

Dec 05
Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

Is Now An Opportune Moment To Examine Bio-Techne Corporation (NASDAQ:TECH)?

Oct 10
Is Now An Opportune Moment To Examine Bio-Techne Corporation (NASDAQ:TECH)?

Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet

Sep 22
Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet

A Look At The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

Sep 01
A Look At The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

At US$80.80, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?

Jul 10
At US$80.80, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?

Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?

Jun 22
Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?

With EPS Growth And More, Bio-Techne (NASDAQ:TECH) Makes An Interesting Case

Jun 07
With EPS Growth And More, Bio-Techne (NASDAQ:TECH) Makes An Interesting Case

Bio-Techne Corporation's (NASDAQ:TECH) Intrinsic Value Is Potentially 25% Below Its Share Price

May 23
Bio-Techne Corporation's (NASDAQ:TECH) Intrinsic Value Is Potentially 25% Below Its Share Price

When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?

Apr 05
When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?

Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet

Mar 21
Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet

Here's Why We Think Bio-Techne (NASDAQ:TECH) Is Well Worth Watching

Mar 06
Here's Why We Think Bio-Techne (NASDAQ:TECH) Is Well Worth Watching

When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?

Jan 03
When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?

We Think Bio-Techne (NASDAQ:TECH) Can Manage Its Debt With Ease

Dec 15
We Think Bio-Techne (NASDAQ:TECH) Can Manage Its Debt With Ease

Should You Be Adding Bio-Techne (NASDAQ:TECH) To Your Watchlist Today?

Nov 30
Should You Be Adding Bio-Techne (NASDAQ:TECH) To Your Watchlist Today?

Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

Nov 17
Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

Bio-Techne releases new AVV viral titer assays

Oct 11

At US$291, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?

Sep 26
At US$291, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?

Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?

Sep 12
Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?

Bio-Techne to seek shareholder approval for 4- for-1 stock split

Sep 01

Is Now The Time To Put Bio-Techne (NASDAQ:TECH) On Your Watchlist?

Aug 29
Is Now The Time To Put Bio-Techne (NASDAQ:TECH) On Your Watchlist?

Bio-Techne releases Quantist Luminex data analysis software

Aug 18

Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

Aug 16
Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

Bio-Teche announces transition plan for CEO Kummeth

Aug 04

Bio-Techne: Resiliency Comes At A Large Premium

Jul 29

Bio-Techne launches HPV detection test RNAscope in Europe for use in throat cancer

Jul 06

Should You Think About Buying Bio-Techne Corporation (NASDAQ:TECH) Now?

Jun 22
Should You Think About Buying Bio-Techne Corporation (NASDAQ:TECH) Now?

Is Bio-Techne (NASDAQ:TECH) Using Too Much Debt?

Jun 09
Is Bio-Techne (NASDAQ:TECH) Using Too Much Debt?

Is Now The Time To Put Bio-Techne (NASDAQ:TECH) On Your Watchlist?

May 26
Is Now The Time To Put Bio-Techne (NASDAQ:TECH) On Your Watchlist?

Estimating The Fair Value Of Bio-Techne Corporation (NASDAQ:TECH)

May 13
Estimating The Fair Value Of Bio-Techne Corporation (NASDAQ:TECH)

Bio-Techne - Exceptional Leverage To Biopharma Growth, And Priced Accordingly

Mar 23

Is Bio-Techne (NASDAQ:TECH) A Risky Investment?

Mar 08
Is Bio-Techne (NASDAQ:TECH) A Risky Investment?

Here's Why I Think Bio-Techne (NASDAQ:TECH) Is An Interesting Stock

Feb 21
Here's Why I Think Bio-Techne (NASDAQ:TECH) Is An Interesting Stock

Earnings and Revenue Growth Forecasts

NasdaqGS:TECH - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/20261,38326535040510
6/30/20251,24822633238613
6/30/20241,14817726331514
12/31/20231,145224225276N/A
9/30/20231,144247215258N/A
6/30/20231,137285216254N/A
3/31/20231,124271233274N/A
12/31/20221,120262252296N/A
9/30/20221,118292285333N/A
6/30/20221,106272280325N/A
3/31/20221,076225302345N/A
12/31/20211,030210308346N/A
9/30/2021985177295335N/A
6/30/2021931140308352N/A
3/31/2021848184225275N/A
12/31/2020799175201250N/A
9/30/2020760248179231N/A
6/30/2020739229153205N/A
3/31/2020755187170216N/A
12/31/2019745195165207N/A
9/30/201973493151183N/A
6/30/201971496156182N/A
3/31/2019703121171191N/A
12/31/201868296154173N/A
9/30/2018661128145165N/A
6/30/2018643126149170N/A
3/31/2018619112135156N/A
12/31/2017599114138160N/A
9/30/201757773N/A162N/A
6/30/201756376N/A144N/A
3/31/201754174N/A129N/A
12/31/201652882N/A141N/A
9/30/2016517101N/A138N/A
6/30/2016499104N/A144N/A
3/31/2016482105N/A145N/A
12/31/201546599N/A138N/A
9/30/2015456107N/A135N/A
6/30/2015452108N/A139N/A
3/31/2015427108N/A140N/A
12/31/2014408116N/A144N/A
9/30/2014380107N/A140N/A
6/30/2014358111N/A137N/A
3/31/2014345113N/A129N/A
12/31/2013330114N/A127N/A
9/30/2013321114N/A127N/A
6/30/2013311113N/A124N/A
3/31/2013310111N/A131N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: TECH's forecast earnings growth (9.9% per year) is above the savings rate (2.3%).

Earnings vs Market: TECH's earnings (9.9% per year) are forecast to grow slower than the US market (13.5% per year).

High Growth Earnings: TECH's earnings are forecast to grow, but not significantly.

Revenue vs Market: TECH's revenue (7.7% per year) is forecast to grow slower than the US market (8.2% per year).

High Growth Revenue: TECH's revenue (7.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: TECH's Return on Equity is forecast to be low in 3 years time (14.5%).


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.